Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Post by Gamestorm7on Aug 29, 2018 9:26pm
170 Views
Post# 28539904

Perfect Storm

Perfect StormFirstly, I want to acknowledge DrHoliday's analysis as excellent. Wuxi would definitely have interest in ICO and I have played this same analysis out in my head before. Now, on to the great news released before the long weekend and official end of "the summer months". ICO is releasing additional data at the upcoming Investor conference. The data which will be released at the conference would attract new eyes one would think. As DrHoliday mentioned, there will be companies trying to buyout ICO with such a small Market Cap at $8M. Well, that market cap is about to go up I believe. The gap down from 2014 is about to close and anyone who can read between the lines will view anything below $0.30 as a good entry point. With Phase I complete the cash burn rate slows significantly, allowing management to find the best value for shareholders in advancing Oral Amp B to Phase II. If an entity tries a takeover, what is considered fair? $100M, $200M or $500M? With the assets in the pipeline, a Big Pharma company may view a $500M investment as worthy when it will generate annual revenues of $1B+ with positive advancement of Oral Amp B to market. The chances of this happening are pretty high considering it is a drug that already has been in use for the last 50 year's and the company has just succeeded in delivery superiority with no toxicity. There is a lot to like about holding shares in this company and the management is delivering in a timely manner. All in all, I don't foresee major dilution coming while the company listens to prospective offers from potential financiers. What do you guys think? GLTA
<< Previous
Bullboard Posts
Next >>